The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation

Author： Williamson D.J.   Shepheard S.L.   Hill R.G.   Hargreaves R.J.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.328, Iss.1, 1997-09, pp. : 61-64

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Flunarizine, an anti-migraine agent, impairs nitroxidergic nerve function in cerebral arteries

By Ayajiki K.   Okamura T.   Toda N.  

European Journal of Pharmacology, Vol. 329, Iss. 1, 1997-06 ,pp. : 49-53

Elsevier

Access to resources Recommend Favorite

The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels

By Akerman S.   Williamson D.J.   Kaube H.   Goadsby P.J.  

European Journal of Pharmacology, Vol. 452, Iss. 2, 2002-10 ,pp. : 223-228

Elsevier

Access to resources Recommend Favorite

Spotlight on Rizatriptan in Migraine

By Wellington K.   Jarvis B.  

CNS Drugs, Vol. 16, Iss. 10, 2002-01 ,pp. : 715-720

Adis International

Access to resources Recommend Favorite

An Economic Evaluation of Rizatriptan in the Treatment of Migraine

By Thompson Melissa  

PharmacoEconomics, Vol. 23, Iss. 8, 2005-01 ,pp. : 837-850

Adis International

Access to resources Recommend Favorite

L-733,060, a novel tachykinin NK 1 receptor antagonist; effects in [Ca 2+ ] i mobilisation, cardiovascular and dural extravasation assays

By Seabrook G.R.   Shepheard S.L.   Williamson D.J.   Tyrer P.   Rigby M.   Cascieri M.A.   Harrison T.   Hargreaves R.J.   Hill R.G.  

European Journal of Pharmacology, Vol. 317, Iss. 1, 1996-12 ,pp. : 129-135

Elsevier

Access to resources Recommend Favorite